Compare Organon & Co. Common Stock (OGN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Snap On Incorporated — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Snap On Incorporated trades at $362.71 (market cap $18.81B). The key difference: Snap On Incorporated is far larger — about 5.2× Organon & Co. Common Stock's market cap, and Snap On Incorporated pays the higher dividend (2.68%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Snap On Incorporated for 38 Days on average.
| OGN | SNA | |
|---|---|---|
Market Cap | $3.62B | $18.81B |
Volume | 2,892,999 | 239,235 |
Sector | Health | Industrials |
52-Week High | $13.81 | $419.31 |
52-Week Low | $5.70 | $328.69 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $11.04B | $18.45B |
Dividend Yield | 0.58% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 19.6% and ROE of 17.58%, while Q2 2026 earnings beat estimates. Recent news highlights gross margin expansion and institutional trading activity.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth and RCI initiatives remain key catalysts, though integration costs and softer OEM demand pose near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
